MLchartDataset catalogue

Nesvacumab

Term · Oncology and biomedicine · MLC-T-ONC-015489

A fully human monoclonal antibody directed against angiopoietin 2 (ANG2) with potential antiangiogenic and antineoplastic activities. Nesvacumab binds to ANG2 and interferes with the interaction between Ang2 and its receptor TEK tyrosine kinas e (Tie2), which may inhibit tumor cell angiogenesis and tumor cell proliferation. ANG2 is upregulated in a variety of cancer cell types and plays a crucial role in angiogenesis.

Table 1. Record
IdentifierMLC-T-ONC-015489
FieldOncology and biomedicine
Synonymsanti-ANG2 monoclonal antibody REGN910; anti-ANG2 MoAb REGN910
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-015489",
  "term": "Nesvacumab",
  "field": "Oncology and biomedicine",
  "definition": "A fully human monoclonal antibody directed against angiopoietin 2 (ANG2) with potential antiangiogenic and antineoplastic activities. Nesvacumab binds to ANG2 and interferes with the interaction between Ang2 and its receptor TEK tyrosine kinas e (Tie2), which may inhibit tumor cell angiogenesis and tumor cell proliferation. ANG2 is upregulated in a variety of cancer cell types and plays a crucial role in angiogenesis.",
  "synonyms": [
    "anti-ANG2 monoclonal antibody REGN910",
    "anti-ANG2 MoAb REGN910"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/nesvacumab/"
}

Record 11,726 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.